Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)

Blood

Volumn 113, Issue 26, 2009, Pages 6528-6532

  Kchour, Ghada ^a   Tarhini, Mahdi ^b   Kooshyar, Mohamad Mehdi ^b   El Hajj, Hiba ^c   Wattel, Eric ^d   Mahmoudi, Mahmoud ^a   Hatoum, Hassan ^c   Rahimi, Hossein ^b   Maleki, Masoud ^a   Rafatpanah, Houshang ^a   Rezaee, S A Rahim ^a   Yazdi, Mojtaba Tabatabaei ^e   Shirdel, Abbas ^b   De Thé, Hugues ^f   Hermine, Olivier ^g   Farid, Reza ^a   Bazarbachi, Ali ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d UNIVERSITÉ LYON 1   (France)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f CNRS   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; ZIDOVUDINE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CD4+ CD25+ T LYMPHOCYTE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LYMPHOCYTE; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; T CELL LEUKEMIA; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN T CELL LEUKEMIA VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PROVIRUS; REMISSION; TOXIC HEPATITIS; VIRUS LOAD;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DRUG ERUPTIONS; DRUG SYNERGISM; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HEPATITIS, TOXIC; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; OXIDES; PROVIRUSES; REMISSION INDUCTION; VIRAL LOAD; ZIDOVUDINE;

EID: 69249235900     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-211821     Document Type: Article

References (24)

1. Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer. 1982;29:631-635. (Pubitemid 12089201)
2. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69:2863-2868.
3. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 1995;86:3619-3639.
4. Waldmann TA, Longo DL, Leonard WJ, et al. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res. 1985;45(9 suppl):4559s-4562s.
5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma: a report from the Lymphoma Study Group (1984-1987). Br J Haematol. 1991;79:428-437.
6. Shimoyama M. Treatment of patients with adult T-cell leukemia-lymphoma: an overview. In: Takatsuki K, Hinuma Y, Yoshida M, eds. Advances in Adult T-Cell Leukemia and HTLV-I Research. Tokyo, Japan: Japan Scientific Societies Press, 1992;39:43-56.
7. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664-672. (Pubitemid 40267851)
8. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemialymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453-459.
9. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-1748.
10. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemialymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751.
11. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S186-S190. (Pubitemid 126735343)
12. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;40:287-294. (Pubitemid 32401385)
13. Hermine O, Allard I, Lévy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276-282. (Pubitemid 36163756)
14. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113:779-784. (Pubitemid 32524403)
15. Sanz MA, Fenaux P, Lo Coco F, European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia: a review of current evidence. Haematologica. 2005;90: 1231-1235.
16. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684. (Pubitemid 121001703)
17. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
18. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-283. (Pubitemid 29019413)
19. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenicinterferon- alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax downregulation and reversal of NF-kappa B activation. Blood. 2000;96:2849-2855. (Pubitemid 30770383)
20. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/ interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101:4576-4582. (Pubitemid 36857830)
21. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/ lymphoma. Hematol J. 2004;5:130-134. (Pubitemid 38519262)
22. Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, Tamura K. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/ refractory adult T-cell leukemia/lymphoma. Haematologica. 2007;92:719-720. (Pubitemid 350144285)
23. Mortreux F, Kazanji M, Gabet AS, de Thoisy B, Wattel E. Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus). J Virol. 2001;75:1083-1089. (Pubitemid 32037314)
24. Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12:466-472.